What is the current valuation of the Immunology Market as of 2024?

The Immunology Market was valued at 109.21 USD Billion in 2024. Read More

What is the projected market size for the Immunology Market by 2035?

The market is projected to reach 220.18 USD Billion by 2035. Read More

What is the expected CAGR for the Immunology Market during the forecast period 2025 - 2035?

The expected CAGR for the Immunology Market during the forecast period 2025 - 2035 is 6.58%. Read More

Which companies are considered key players in the Immunology Market?

Key players in the Immunology Market include AbbVie, Roche, Johnson & Johnson, Merck & Co., Amgen, Gilead Sciences, Sanofi, Bristol-Myers Squibb, and Novartis. Read More

How much is the Immunotherapy Type segment projected to grow by 2035?

The Immunotherapy Type segment is projected to grow from 109.21 USD Billion in 2024 to a significantly higher valuation by 2035. Read More

What test types are utilized in the Immunology Market?

Test types utilized in the Immunology Market include Flow Cytometry, ELISA, Western Blotting, Immunohistochemistry, and Immunofluorescence. Read More

Immunology Market

Q: What are the major segments of the Immunology Market based on immunotherapy type?

Major segments based on immunotherapy type include Checkpoint Inhibitors, Adoptive Cell Therapy, Oncolytic Viruses, Cancer Vaccines, and Immunomodulators. Read More

Q: What applications are driving growth in the Immunology Market?

Applications driving growth include Cancer, Autoimmune Diseases, Infectious Diseases, Neurological Disorders, and Allergic Diseases. Read More

Q: What are the anticipated trends in target types within the Immunology Market?

Anticipated trends in target types include Antibody-Based Therapies, Cell-Based Therapies, Gene Therapies, Small Molecule Therapies, and Peptides. Read More

Q: Which end users are expected to dominate the Immunology Market?

End users expected to dominate the market include Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, and Biotechnology Companies. Read More

ID: MRFR/HC/28516-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Immunology Market Research Report: Size, Share, Trend Analysis By Immunotherapy Type (Checkpoint Inhibitors, Adoptive Cell Therapy, Oncolytic Viruses, Cancer Vaccines, Immunomodulators), By Applications (Cancer, Autoimmune Diseases, Infectious Diseases, Neurological Disorders, Allergic Diseases), By Target Type (Antibody-Based Therapies, Cell-Based Therapies, Gene Therapies, Small Molecule Therapies, Peptides), By End Users (Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Biotechnology Companies), By Test Type (Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Immunohistochemistry, Immunofluorescence) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Immunotherapy Type (USD Billion) | |
  1. 4.1.1 Checkpoint Inhibitors | |
  2. 4.1.2 Adoptive Cell Therapy | |
  3. 4.1.3 Oncolytic Viruses | |
  4. 4.1.4 Cancer Vaccines | |
  5. 4.1.5 Immunomodulators |
2. 4.2 Healthcare, BY Application (USD Billion) | |
  1. 4.2.1 Cancer | |
  2. 4.2.2 Autoimmune Diseases | |
  3. 4.2.3 Infectious Diseases | |
  4. 4.2.4 Neurological Disorders | |
  5. 4.2.5 Allergic Diseases |
3. 4.3 Healthcare, BY Target Type (USD Billion) | |
  1. 4.3.1 Antibody-Based Therapies | |
  2. 4.3.2 Cell-Based Therapies | |
  3. 4.3.3 Gene Therapies | |
  4. 4.3.4 Small Molecule Therapies | |
  5. 4.3.5 Peptides |
4. 4.4 Healthcare, BY End User (USD Billion) | |
  1. 4.4.1 Hospitals | |
  2. 4.4.2 Clinics | |
  3. 4.4.3 Research Institutes | |
  4. 4.4.4 Pharmaceutical Companies | |
  5. 4.4.5 Biotechnology Companies |
5. 4.5 Healthcare, BY Test Type (USD Billion) | |
  1. 4.5.1 Flow Cytometry | |
  2. 4.5.2 Enzyme-Linked Immunosorbent Assay (ELISA) | |
  3. 4.5.3 Western Blotting | |
  4. 4.5.4 Immunohistochemistry | |
  5. 4.5.5 Immunofluorescence |
6. 4.6 Healthcare, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 AbbVie (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Roche (CH) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Johnson & Johnson (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Merck & Co. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Amgen (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Gilead Sciences (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Sanofi (FR) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bristol-Myers Squibb (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Novartis (CH) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
7. 6.4 US MARKET ANALYSIS BY APPLICATION |
8. 6.5 US MARKET ANALYSIS BY TARGET TYPE |
9. 6.6 US MARKET ANALYSIS BY END USER |
10. 6.7 US MARKET ANALYSIS BY TEST TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY APPLICATION |
13. 6.10 CANADA MARKET ANALYSIS BY TARGET TYPE |
14. 6.11 CANADA MARKET ANALYSIS BY END USER |
15. 6.12 CANADA MARKET ANALYSIS BY TEST TYPE |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
18. 6.15 GERMANY MARKET ANALYSIS BY APPLICATION |
19. 6.16 GERMANY MARKET ANALYSIS BY TARGET TYPE |
20. 6.17 GERMANY MARKET ANALYSIS BY END USER |
21. 6.18 GERMANY MARKET ANALYSIS BY TEST TYPE |
22. 6.19 UK MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
23. 6.20 UK MARKET ANALYSIS BY APPLICATION |
24. 6.21 UK MARKET ANALYSIS BY TARGET TYPE |
25. 6.22 UK MARKET ANALYSIS BY END USER |
26. 6.23 UK MARKET ANALYSIS BY TEST TYPE |
27. 6.24 FRANCE MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
28. 6.25 FRANCE MARKET ANALYSIS BY APPLICATION |
29. 6.26 FRANCE MARKET ANALYSIS BY TARGET TYPE |
30. 6.27 FRANCE MARKET ANALYSIS BY END USER |
31. 6.28 FRANCE MARKET ANALYSIS BY TEST TYPE |
32. 6.29 RUSSIA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
33. 6.30 RUSSIA MARKET ANALYSIS BY APPLICATION |
34. 6.31 RUSSIA MARKET ANALYSIS BY TARGET TYPE |
35. 6.32 RUSSIA MARKET ANALYSIS BY END USER |
36. 6.33 RUSSIA MARKET ANALYSIS BY TEST TYPE |
37. 6.34 ITALY MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
38. 6.35 ITALY MARKET ANALYSIS BY APPLICATION |
39. 6.36 ITALY MARKET ANALYSIS BY TARGET TYPE |
40. 6.37 ITALY MARKET ANALYSIS BY END USER |
41. 6.38 ITALY MARKET ANALYSIS BY TEST TYPE |
42. 6.39 SPAIN MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
43. 6.40 SPAIN MARKET ANALYSIS BY APPLICATION |
44. 6.41 SPAIN MARKET ANALYSIS BY TARGET TYPE |
45. 6.42 SPAIN MARKET ANALYSIS BY END USER |
46. 6.43 SPAIN MARKET ANALYSIS BY TEST TYPE |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY TARGET TYPE |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY END USER |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
54. 6.51 CHINA MARKET ANALYSIS BY APPLICATION |
55. 6.52 CHINA MARKET ANALYSIS BY TARGET TYPE |
56. 6.53 CHINA MARKET ANALYSIS BY END USER |
57. 6.54 CHINA MARKET ANALYSIS BY TEST TYPE |
58. 6.55 INDIA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
59. 6.56 INDIA MARKET ANALYSIS BY APPLICATION |
60. 6.57 INDIA MARKET ANALYSIS BY TARGET TYPE |
61. 6.58 INDIA MARKET ANALYSIS BY END USER |
62. 6.59 INDIA MARKET ANALYSIS BY TEST TYPE |
63. 6.60 JAPAN MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
64. 6.61 JAPAN MARKET ANALYSIS BY APPLICATION |
65. 6.62 JAPAN MARKET ANALYSIS BY TARGET TYPE |
66. 6.63 JAPAN MARKET ANALYSIS BY END USER |
67. 6.64 JAPAN MARKET ANALYSIS BY TEST TYPE |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY TARGET TYPE |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY END USER |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
73. 6.70 MALAYSIA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
74. 6.71 MALAYSIA MARKET ANALYSIS BY APPLICATION |
75. 6.72 MALAYSIA MARKET ANALYSIS BY TARGET TYPE |
76. 6.73 MALAYSIA MARKET ANALYSIS BY END USER |
77. 6.74 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
78. 6.75 THAILAND MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
79. 6.76 THAILAND MARKET ANALYSIS BY APPLICATION |
80. 6.77 THAILAND MARKET ANALYSIS BY TARGET TYPE |
81. 6.78 THAILAND MARKET ANALYSIS BY END USER |
82. 6.79 THAILAND MARKET ANALYSIS BY TEST TYPE |
83. 6.80 INDONESIA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
84. 6.81 INDONESIA MARKET ANALYSIS BY APPLICATION |
85. 6.82 INDONESIA MARKET ANALYSIS BY TARGET TYPE |
86. 6.83 INDONESIA MARKET ANALYSIS BY END USER |
87. 6.84 INDONESIA MARKET ANALYSIS BY TEST TYPE |
88. 6.85 REST OF APAC MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
89. 6.86 REST OF APAC MARKET ANALYSIS BY APPLICATION |
90. 6.87 REST OF APAC MARKET ANALYSIS BY TARGET TYPE |
91. 6.88 REST OF APAC MARKET ANALYSIS BY END USER |
92. 6.89 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
95. 6.92 BRAZIL MARKET ANALYSIS BY APPLICATION |
96. 6.93 BRAZIL MARKET ANALYSIS BY TARGET TYPE |
97. 6.94 BRAZIL MARKET ANALYSIS BY END USER |
98. 6.95 BRAZIL MARKET ANALYSIS BY TEST TYPE |
99. 6.96 MEXICO MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
100. 6.97 MEXICO MARKET ANALYSIS BY APPLICATION |
101. 6.98 MEXICO MARKET ANALYSIS BY TARGET TYPE |
102. 6.99 MEXICO MARKET ANALYSIS BY END USER |
103. 6.100 MEXICO MARKET ANALYSIS BY TEST TYPE |
104. 6.101 ARGENTINA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
105. 6.102 ARGENTINA MARKET ANALYSIS BY APPLICATION |
106. 6.103 ARGENTINA MARKET ANALYSIS BY TARGET TYPE |
107. 6.104 ARGENTINA MARKET ANALYSIS BY END USER |
108. 6.105 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET TYPE |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY TARGET TYPE |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY END USER |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY TARGET TYPE |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY END USER |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
125. 6.122 REST OF MEA MARKET ANALYSIS BY IMMUNOTHERAPY TYPE |
126. 6.123 REST OF MEA MARKET ANALYSIS BY APPLICATION |
127. 6.124 REST OF MEA MARKET ANALYSIS BY TARGET TYPE |
128. 6.125 REST OF MEA MARKET ANALYSIS BY END USER |
129. 6.126 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
130. 6.127 KEY BUYING CRITERIA OF HEALTHCARE |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF HEALTHCARE |
133. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
135. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE |
136. 6.133 HEALTHCARE, BY IMMUNOTHERAPY TYPE, 2024 (% SHARE) |
137. 6.134 HEALTHCARE, BY IMMUNOTHERAPY TYPE, 2024 TO 2035 (USD Billion) |
138. 6.135 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
139. 6.136 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
140. 6.137 HEALTHCARE, BY TARGET TYPE, 2024 (% SHARE) |
141. 6.138 HEALTHCARE, BY TARGET TYPE, 2024 TO 2035 (USD Billion) |
142. 6.139 HEALTHCARE, BY END USER, 2024 (% SHARE) |
143. 6.140 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
144. 6.141 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
145. 6.142 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY TEST TYPE, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY TEST TYPE, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY TEST TYPE, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY TEST TYPE, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY TEST TYPE, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY TEST TYPE, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY TEST TYPE, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY TEST TYPE, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY TEST TYPE, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY TEST TYPE, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY TEST TYPE, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY TEST TYPE, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY TEST TYPE, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY TEST TYPE, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY TEST TYPE, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY TEST TYPE, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY TEST TYPE, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY TEST TYPE, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY TEST TYPE, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY TEST TYPE, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY TEST TYPE, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY TEST TYPE, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY TEST TYPE, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY TEST TYPE, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY TEST TYPE, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY TEST TYPE, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY TEST TYPE, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY TEST TYPE, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY IMMUNOTHERAPY TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY TARGET TYPE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY END USER, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY TEST TYPE, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Immunotherapy Type (USD Billion, 2025-2035)

Checkpoint Inhibitors
Adoptive Cell Therapy
Oncolytic Viruses
Cancer Vaccines
Immunomodulators

Healthcare By Application (USD Billion, 2025-2035)

Cancer
Autoimmune Diseases
Infectious Diseases
Neurological Disorders
Allergic Diseases

Healthcare By Target Type (USD Billion, 2025-2035)

Antibody-Based Therapies
Cell-Based Therapies
Gene Therapies
Small Molecule Therapies
Peptides

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Research Institutes
Pharmaceutical Companies
Biotechnology Companies

Healthcare By Test Type (USD Billion, 2025-2035)

Flow Cytometry
Enzyme-Linked Immunosorbent Assay (ELISA)
Western Blotting
Immunohistochemistry
Immunofluorescence

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓